Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
Chinook Therapeutics
|
| gptkbp:acquisitionYear |
2020
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focus |
oncology
immunotherapy |
| gptkbp:founded |
2000
|
| gptkbp:founder |
Stephen Isaacs
|
| gptkbp:headquarters_location |
gptkb:Berkeley,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Aduro Biotech
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableCollaboration |
gptkb:Johnson_&_Johnson
gptkb:Merck gptkb:Novartis |
| gptkbp:notableProduct |
LADD (Live, Attenuated, Double-Deleted) immunotherapy platform
STING pathway activators |
| gptkbp:numberOfEmployees |
approximately 100 (at time of acquisition)
|
| gptkbp:status |
defunct (merged with Chinook Therapeutics)
|
| gptkbp:stockSymbol |
ADRO
|
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:website |
https://www.aduro.com/
|
| gptkbp:bfsParent |
gptkb:Tom_Dubensky
|
| gptkbp:bfsLayer |
7
|